E
BIIB icon

Ergoteles’s Biogen BIIB Stock Holding History

Ergoteles’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,632
Closed -$454K – 1068
2023
Q1 		$454K Sell
1,632
-10,087
-86% -$2.79M 0.02% 768
2022
Q4 		$3.25M Buy
+11,719
New +$3.31M 0.12% 174
2021
Q3 		– Sell
-39,277
Closed -$13.6M – 1230
2021
Q2 		$13.6M Buy
+39,277
New +$11.9M 0.31% 90
2021
Q1 		– Sell
-52,452
Closed -$12.8M – 809
2020
Q4 		$12.8M Buy
52,452
+23,252
+80% +$6M 0.43% 61
2020
Q3 		$8.28M Buy
+29,200
New +$8.14M 1.1% 19

Other funds holding BIIB

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Ergoteles's BIIB Position: Q2 2023 in Review

Ergoteles sold out of Biogen (BIIB) in Q2 2023, closing a stake of 1,632 shares — an estimated $454K sold.

Ergoteles first reported a position in BIIB in Q3 2020 and held it in 5 quarters. The position peaked at $13.6M in Q2 2021. 1,008 funds tracked by Wall St. Rank hold BIIB as of Q2 2023.

  • Ergoteles reported no remaining Biogen position as of Q2 2023 after selling out during the quarter.
  • Ergoteles sold 1,632 Biogen shares in Q2 2023, an estimated $454K.
  • Ergoteles first reported a position in Biogen in Q3 2020 and held it in 5 quarters.
  • Ergoteles's Biogen position peaked at $13.6M in Q2 2021.
  • 1,008 funds tracked by Wall St. Rank held Biogen as of Q2 2023.

Based on Ergoteles's 13F filing for Q2 2023, filed 14 Aug 2023.